NPCENeuroPace, Inc.

NeuroPace Inc (NPCE) raises full-year guidance on 21.3% RNS revenue growth, while navigating an unexpected FDA request for additional IGE data.

NPCE's IGE expansion faces a regulatory delay, shifting focus to rising RNS adoption as the company works through the FDA review process.

NPCE's stronger RNS adoption, narrowing losses and AI expansion support growth, but premium valuation, liquidity and regulatory risks warrant patience.

NeuroPace's stronger RNS growth, raised 2026 guidance and AI expansion face a less certain IGE regulatory path after the FDA setback.

NeuroPace's Q2 revenues rise 17.1% as RNS demand strengthens, while a narrower loss and higher 2026 outlook highlight continued momentum.

Moby summary of NeuroPace, Inc.'s Q2 2026 earnings call

NeuroPace (NASDAQ:NPCE) reported second-quarter revenue growth driven by continued adoption of its RNS System for adult focal epilepsy, while raising its full-year revenue and adjusted EBITDA outlook. The company also said it is pursuing additional discussions with the U.S. Food and Drug Administrat

NeuroPace (NPCE) delivered earnings and revenue surprises of +5.26% and +0.64%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

CVRx (CVRX) delivered earnings and revenue surprises of -1.92% and +0.40%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

NeuroPace (NASDAQ:NPCE) said the U.S. Food and Drug Administration determined that its premarket approval supplement seeking to expand the RNS System indication to patients with medication-resistant idiopathic generalized epilepsy, or IGE, was not approvable in its current form. The company said th

NPCE's RNS adoption, referral growth and AI innovation support expansion, while IGE timing and investments may pressure near-term profits.